Retinol inhibits the invasion of retinoic acid-resistant colon cancer cells in vitro and decreases matrix metalloproteinase mRNA, protein, and activity levels

Nutrition and Cancer

Volumn 57, Issue 1, 2007, Pages 66-77

  Eun, Young Park ^a   Wilder, Erik T ^a   Lane, Michelle A ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; DACTINOMYCIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOL;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY;

EID: 34249880147     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580701268238     Document Type: Article

References (56)

1. American Cancer Society: Cancer Facts and Figures. American Cancer Society, 2005, pp 12-14.
2. Leeman MF, Curran S, and Murray GI: New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201, 528-534, 2003.
3. Mook OR, Frederiks WM, and Van Noorden CJ: The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705, 69-89, 2004.
4. Ogawa M, Ikeuchi K, Watanabe M, Etoh K, Kobayashi T, et al.: Expression of matrix metalloproteinase 7. laminin and type IV collagen-associated liver metastasis in human colorectal cancer: immunohistochemical approach. Hepatogastroenterology 52, 875-880, 2005.
5. Pesta M, Holubec L Jr, Topolcan O, Cerna M, Rupert K, et al.: Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 25, 3387-3391, 2005.
6. Hornebeck W, Lambert E, Petitfrére E, and Bernard P: Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression. Biochimie 87, 377-383, 2005.
7. Weinzweig J, Tattini C, Lynch S, Zienowicz R, Weinzweig N, et al.: Investigation of the growth and metastasis of malignant melanoma in a murine model: the role of supplemental vitamin A. Plast Reconstr Surg 112, 152-158: discussion 159-161, 2003.
8. Qiao W, Chen Y, Chen Z, Chen F, and Su W: Effects of retinoic acid on metastasis and its related proteins in gastric cancer cells in vivo and in vitro. Acta Pharmacol Sin 23, 835-841, 2002.
9. Adachi Y, Fumio I, Yamamoto H, Iku S, Matsuno K, et al.: Retinoic acids reduce matrilysin (matrix metalloproteinase 7) and inhibit tumor cell invasion in human colon cancer. Tumor Biol 22, 247-253, 2001.
10. Soprano DR, Qin P, and Soprano KJ: Retinoic acid receptors and cancers. Annu Rev Nutr 24, 201-221, 2004.
11. Sonneveld E, van den Brink CE, van der Leede BM, Schulkes R, Petkovich M, et al.: Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. Cell Growth Differ 9, 629-637, 1998.
12. Nicke B, Kaiser A, Wiedenmann B, Riecken EO, and Rosewicz S: Retinoic acid receptor a mediates growth inhibition by retinoids in human colon carcinoma HT29 cells. Biochem Biophys Res Commun 21, 572-577, 1999.
13. Nicke B, Riecken EO, and Rosewicz S: Induction of retinoic acid receptor b mediates growth inhibition in retinoid resistant human colon carcinoma cells. Gut 45, 51-57, 1999.
14. Lee MO, Man SY, Jiang S, Park JH, and Kim SJ: Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem Pharmacol 59, 485-496, 2000.
15. Vogel S, Gamble MV, and Blaner WS: Biosynthesis, absorption, metabolism and transport of retinoids. In Retinoids: The Biochemical and Molecular Basis of Vitamin A and Retinoid Action, Nau H and Blaner WS (eds.). Berlin: Springer-Verlag, 1999, pp 31-95.
16. Smith FR and Goodman DS: The effects of diseases of the liver, thyroid, and kidneys on the transport of vitamin A in human plasma. J Clin Invest 50, 2426-2436, 1971.
17. Park EY, Dillard A, Williams EA, Pepper MR, Wilder ET, et al.: Retinol inhibits the growth of retinoic acid-sensitive and -resistant colon cancer cells through a retinoic acid receptor-independent mechanism. Cancer Res 65, 9923-9933, 2005.
18. Baugher PJ, Krishnamoorthy L, Price JE, and Dharmawardhane SF: Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast Cancer Res 7, R965-R974, 2005.
19. -DDC method. Methods 25, 402-408, 2001.
20. Chung TW, Lee YC, Ko JH, and Kim CH: Hepatitis B virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res 63, 3453-3458, 2003.
21. Waliszewski P, Waliszewska MK, Gupta M, Milsom JW, and Hurst RE: Expression of retinoid-responsive genes occurs in colorectal carcinoma-derived cells irrespective of the presence of resistance to all-trans retinoic acid. J Surg Oncol Suppl 66, 156-167, 1997.
22. Klein ES, Pino ME, Johnson AT, Davies PJ, Nagpal S, et al.: Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists. J Biol Chem 271, 22692-22696, 1996.
23. Yamamoto H, Iku S, Adachi Y, Imsumran A, Taniguchi H, et al.: Association of trypsin expression with tumour progression and matritysin expression in human colorectal cancer. J Pathol 199, 176-184, 2003.
24. Seiler N, Schneider Y, Gosse F, Schleiffer R, and Raul F: Polyploidisation of metastatic colon carcinoma cells by microtubule and tubulin interacting drugs: effect on proteolytic activity and invasiveness. Int J Oncol 25, 1039-1048, 2004.
25. Jette C, Peterson PW, Sandoval IT, Manos EJ, Hadley E, et al.: The tumor suppressor adenomatous polyposis coli and caudal related homeodomain protein regulate expression of retinol dehydrogenase L. J Biol Chem 279, 34397-34405, 2004.
26. Wu S, Zhang ZP, Zhang D, Soprano DR, and Soprano KJ: Reduction of both RAR and RXR levels is required to maximally alter sensitivity of CA-OV3 ovarian tumor cells to growth suppression by all-trans-retinoic acid. Exp Cell Res 237, 118-126, 1997.
27. Liu H, Zang C, Fenner MH, Possinger K, and Elstner E: PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat 79, 63-74, 2003.
28. Lateef H, Stevens MJ, and Varani J: All-trans-retinoic acid suppresses matrix metalloproteinase activity and increases collagen synthesis in diabetic human skin in organ culture. Am J Pathol 165, 167-174, 2004.
29. Benbow U, Schoenermark MP, Orndorff KA, Givan AL, and Brinckerhoff CE: Human breast cancer cells activate procollagenase-1 and invade type I collagen: invasion is inhibited by all-trans retinoic acid. Clin Exp Metastasis 17, 231-238, 1999.
30. Benbow U, Schoenermark MP, Mitchell TI, Rutter JL, Shimokawa K, et al.: A novel host/tumor cell interaction activates matrix metalloproteinase I and mediates invasion through type I collagen. J Biol Chem 274, 25371-25378, 1999.
31. Nwankwo JO: Anti-metastatic activities of all-trans retinoic acid, indole-3-carbinol and (+)-catechin in Dunning rat invasive prostate adenocarcinoma cells. Anticancer Res 22, 4129-4135, 2002.
32. Andela VB and Rosier RN: The proteosome inhibitor MG132 attenuates retinoic acid receptor trans-activation and enhances transrepression of nuclear factor kappaB. Potential relevance to chemopreventive interventions with retinoids. Mol Cancer 3, 8, 2004.
33. Collins HM, Morris TM, and Watson SA: Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer 84, 1664-1670, 2001.
34. Ornstein DL and Cohn KH: Balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumors compared to normal colonic epithelium. Dig Dis Sci 47, 1821-1830, 2002.
35. Koumura H, Sugiyama Y, Kunieda K, and Saji S: Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer. Gan To Kagaku Ryoho 24 (suppl 2), 324-331, 1997.
36. Tomita T and Iwata K: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dis Colon Rectum 39, 1255-1264, 1996.
37. Chan CC, Menges M, Orzechowski HD, Orendain N, Pistorius G, et al.: Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas. Int J Colorectal Dis 16, 133-140, 2001.
38. Baker EA and Leaper DJ: Measuring gelatinase activity in colorectal cancer. Eur J Surg Oncol 28, 24-29, 2002.
39. Emmert-Buck MR, Roth MJ, Zhuang Z, Campo E, Rozhin J, et al.: Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol 145, 1285-1290, 1994.
40. Zeng ZS and Guillem JG: Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal cancer stromal cells. Br J Cancer 74, 1161-1167, 1996.
41. Okada N, Ishida H, Murata N, Hashimoto D, Seyama Y, et al.: Matrix metalloproteinase-2 and -9 in bile as a marker of liver metastasis in colorectal cancer. Biochem Biophys Res Commun 288, 212-216, 2001.
42. Jeziorska M, Haboubi NY, Schofield PF, Ogata Y, Nagase H, et al.: Distribution of gelatinase B (MMP-9) and type IV collagen in colorectal carcinoma. Int J Colorectal Dis 9, 141-148, 1994.
43. Martin DC, Rüther U, Sanchez-Sweatman OH, Orr FW, and Khokha R: Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene 13, 569-576, 1996.
44. Khokha R: Suppression of the tumorigenic and metastatic abilities of nuirine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. JNCI 86, 299-304, 1994.
45. Ikenaka Y, Yoshiji H, Kuriyama S, Yoshii J, Noguchi R, et al.: Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer 105, 340-346, 2003.
46. Zeng ZS and Guillem JG: Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase I mRNA expression in human colorectal cancer and liver metastases. Br J Cancer 72, 575-582, 1995.
47. Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, et al.: Clinical significance of tissue inhibitor of metalloproteimise expression in gastric carcinoma. Br J Cancer 76, 531-536, 1997.
48. Fong KM, Kida Y, Zimmerman PV, and Smith PJ: TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 2, 1369-1372, 1996.
49. Kossakowska AE, Urbanski SJ, and Edwards DR: Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. Blood 77, 2475-2481, 1991.
50. Bertaux B, Hornebeck W, Eisen AZ, and Dubertret L: Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 97, 679-685, 1991.
51. Chesler L, Golde DW, Bersch N, and Johnson MD: Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 86, 4506-4515, 1995.
52. Yamashita K, Suzuki M, Iwata H, Koike T, Hamaguchi M, et al.: Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). FEBS Lett 396, 103-107, 1996.
53. Hornebeck W: Down-regulation of tissue inhibitor of matrix metalloprotease-1 (TIMP-1) in aged human skin contributes to matrix degradation and impaired cell growth and survival. Pathol Biol 51, 569-573, 2003.
54. Barille S, Bataille R, Rapp MJ, Harousseau JL, and Amiot M: Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol 163, 5723-5728, 1999.
55. Ohta S, Lai EW, Pang AL, Brouwers FM, Chan WY, et al.: Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int J Cancer 114, 139-143, 2005.
56. Yuan H, Kamata M, Xie YM, and Chen IS: Increased levels of Wee-1 kinase in G(2) are necessary for Vpr- and gamma irradiation-induced G(2) arrest. J Virol 78, 8183-8190, 2004.